Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
7.275 USD | -4.28% | -12.63% | +126.14% |
May. 28 | Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion | MT |
May. 15 | Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+126.14% | 880M | |
+19.13% | 125B | |
+14.62% | 108B | |
-4.49% | 24.57B | |
+3.23% | 22.82B | |
-10.44% | 18.19B | |
-41.74% | 16.54B | |
-13.31% | 16.5B | |
+2.83% | 13.39B | |
+29.13% | 11.1B |
- Stock Market
- Equities
- ARQT Stock
- News Arcutis Biotherapeutics, Inc.
- Mizuho Securities Raises Price Target on Arcutis Biotherapeutics to $17 From $16, Maintains Buy Rating